A Phase 2 interventional study of Cyclophosphamide and Fludarabine in Leukemia, Lymphocytic, Chronic, B-Cell, sponsored by Hoffmann-La Roche. Completed at 33 sites in Spain. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2019-01-16.
Sponsored by Hoffmann-La Roche · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 155 studies testing cyclophosphamide in Leukemia, Lymphocytic, Chronic, B-Cell — 3 open to participants now, 11 under way, none of them phase 3. Cyclophosphamide · Leukemia, Lymphocytic, Chronic, B-Cell.
Among the 155 studies testing cyclophosphamide in Leukemia, Lymphocytic, Chronic, B-Cell, this one is the 39th largest by enrollment of the 145 interventional ones that give a count, is one of 8 that started in 2007, is one of 100 in phase 2, and was the 74th registered.
2,036 studies on the registry are indexed under Leukemia, Lymphocytic, Chronic, B-Cell; 237 are open to participants now.
Browse Leukemia, Lymphocytic, Chronic, B-Cell studies →3 of the 155 studies testing cyclophosphamide in Leukemia, Lymphocytic, Chronic, B-Cell are open now, in 1 country. Recruiting first, the newest first:
Mayo Clinic · Sites in United States
Ages 18+
Medical University of South Carolina · Sites in United States
Ages 18+
Masonic Cancer Center, University of Minnesota · Sites in United States
Ages up to 75
By country, each count listing its studies:
Cyclophosphamide: first FDA approval 1959 (CYTOXAN). What it is approved for, and how studies give it, is on its page →
Of the 188 Leukemia, Lymphocytic, Chronic, B-Cell studies recruiting now, 150 (80%) set no upper age limit and 15 (8%) stop at 75 or younger; 17 take children under 18; 13 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
155 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 35 · Phase 2 114 · Phase 3 11 · Phase 4 3
First in 1988; this study’s year is marked. 8 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 86 is above the median of 39 across 1,603 interventional studies indexed under Leukemia, Lymphocytic, Chronic, B-Cell.
Median enrollment 49 across the 145 interventional studies. Of the 132 that completed or were terminated, 77 (58%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 155 have an industry lead sponsor. The 10 most frequent:
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.
Of its 330 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
48 studies in Leukemia, Lymphocytic, Chronic, B-Cell by Hoffmann-La Roche: 1 open now, 2 under way, none of them phase 3. Of 46 finished, 28 (61%) have results posted.
Among the 48 studies in Leukemia, Lymphocytic, Chronic, B-Cell by Hoffmann-La Roche, this one is the 23rd largest by enrollment of the 36 interventional ones that give a count, is one of 3 that started in 2007, is one of 13 in phase 2, and was the 5th registered.
Hoffmann-La Roche’s Leukemia, Lymphocytic, Chronic, B-Cell studies by the year they started, since 2003.
4 of the studies testing cyclophosphamide in Leukemia, Lymphocytic, Chronic, B-Cell that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT00466531Memorial Sloan Kettering Cancer CenterTreatment of Relapsed or Chemotherapy Refractory Chronic Lymphocytic Leukemia or Indolent B Cell Lymphoma Using Autologous T Cells Genetically Targeted to the B Cell Specific Antigen CD19 | 2026-12 |
| NCT06001385Center for International Blood and Marrow Transplant ResearchHLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation With Reduced Dose Post Transplantation Cyclophosphamide GvHD Prophylaxis | 2026-12-24 |
| NCT02153580City of Hope Medical CenterCellular Immunotherapy Following Chemotherapy in Treating Patients With Recurrent Non-Hodgkin Lymphomas, Chronic Lymphocytic Leukemia, or B-Cell Prolymphocytic Leukemia | 2027-08-11 |
| NCT05805605Masonic Cancer Center, University of MinnesotaAllo HSCT Using RIC and PTCy for Hematological Diseases | 2027-10-22 |
Add all 4 to your calendar (.ics) → With an account.
Among the 155 studies testing cyclophosphamide in Leukemia, Lymphocytic, Chronic, B-Cell, from their registry updates:
Among Hoffmann-La Roche’s 48 in Leukemia, Lymphocytic, Chronic, B-Cell:
This tab as a report to print or save as PDF → With an account.
This single arm study will assess the efficacy and safety of rituximab in combination with fludarabine and cyclophosphamide, followed by rituximab maintenance therapy, as first line treatment of participants with CLL.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive 6 cycles (cycle length = 28 days) of treatment with rituximab (375 milligrams per square meter \[mg/m\^2\] as intravenous \[IV\] infusion on Day 0 of Cycle 1 and 500 mg/m\^2 as IV infusion on Day 1 of Cycles 2-6); fludarabine (25 mg/m\^2 on Days 1-3) and cyclophosphamide (250 mg/m\^2 on Days 1-3). Participants with a partial or complete response and appropriate neutrophil conditions will receive maintenance treatment with rituximab (375 mg/m\^2 as IV infusion every 2 months) from 3 months after Day 1 Cycle 6 up to a total of 18 doses or up to 3 years after Cycle 6.
Drug: Cyclophosphamide · Drug: Fludarabine · Drug: Rituximab
Cyclophosphamide 250 mg/m\^2 as IV infusion will be administered on Days 1-3 of first six 28-day cycles.
Fludarabine 25 mg/m\^2 as IV infusion will be administered on Days 1-3 of first six 28-day cycles.
Rituximab 375 mg/m\^2 as IV infusion will be administered on Day 0 of Cycle 1; 500 mg/m\^2 as IV infusion will be administered on Day 1 of Cycle 2-6; and 375 mg/m\^2 as IV infusion every 2 months from 3 months after Day 1 Cycle 6 up to a total of 18 doses or up to 3 years after Cycle 6.
Also known as: MabThera, Rituxan
Percentage of Participants With CR Achieved After the Rituximab, Fludarabine, and Cyclophosphamide Regimen
CR was defined as no adenopathies (ADPs) and visceromegalies (VSMs) in physical examination (PE); no general symptoms (Sx); lymphocytes (Lymph) in peripheral blood less than (\<) 4000 per cubic millimeter (mm\^3); normalization of peripheral blood parameters: neutrophils (Neut) greater than (\>) 1500/mm\^3, platelets (Plt) \>100,000/mm\^3, hemoglobin (Hb) \>11 grams per deciliter (g/dL) without transfusion; normocellular bone marrow (BM) with \<30% Lymph; BM aspirate/biopsy with no evidence of infiltration of lymphoid nodules.
Time frame: Month 9
Percentage of Participants With Clinical Response of CR or PR as Assessed by Multiparameter Flow Cytometry
CR was defined as no ADPs and VSMs in PE; no general Sx; Lymph in peripheral blood \<4000/mm\^3; normalization of peripheral blood parameters: Neut \>1500/mm\^3, Plt \>100,000/mm\^3, Hb \>11 g/dL without transfusion; normocellular BM with \<30% Lymph; BM aspirate/biopsy with no evidence of infiltration of lymphoid nodules. PR was defined as decrease \>50% in Lymph in peripheral blood; reduction in ADPs \>50% in total sum of up to 6 ADPs or in the baseline ADP of largest diameter (LD), no new ADP or enlargement of a prior ADP; \>50% decrease in VSM; Neut \>1500/mm\^3 or \>50% increase from Baseline; Plt \>100,000/mm\^3 or \>50% increase from Baseline; Hb \>11.0 g/dL or \>50% increase from Baseline value without transfusion. Participants who met all CR criteria but had persistent anemia or thrombocytopenia were considered as PR.
Time frame: Post-Induction Phase (IP): at 6 months; during Maintenance Phase (MP): at Cycles 9, 12, 15, 18 (cycle length = 2 months); during Follow-Up (FU): at Follow-Up Months 6, 12, 18, 24, 30, 36
Percentage of Participants With Clinical Response of CR or PR Among Participants With Negative Minimal Residual Disease (MRD) as Assessed by Multiparameter Flow Cytometry
CR: no ADPs and VSMs in PE; no general Sx; Lymph in peripheral blood \<4000/mm\^3; normalization of peripheral blood parameters: Neut \>1500/mm\^3, Plt \>100,000/mm\^3, Hb \>11 g/dL without transfusion; normocellular BM with \<30% Lymph; BM aspirate/biopsy with no evidence of infiltration of lymphoid nodules. PR: decrease \>50% in Lymph in peripheral blood; reduction in ADPs \>50% in total sum of up to 6 ADPs or in the baseline ADP of largest diameter (LD), no new ADP or enlargement of a prior ADP; \>50% decrease in VSM; Neut \>1500/mm\^3 or \>50% increase from Baseline; Plt \>100,000/mm\^3 or \>50% increase from Baseline; Hb \>11.0 g/dL or \>50% increase from Baseline value without transfusion. Participants who met all CR criteria but had persistent anemia or thrombocytopenia were considered as PR. Negative MRD: Lymph \<0.01% of all white blood cells (WBCs) in blood or BM after two consecutive measurements. Analysis performed only in blood during the Maintenance Phase and Follow-Up.
Time frame: Post-Induction Phase: at 6 months; during Maintenance Phase: at Cycles 9, 12, 15, 18 (cycle length = 2 months); during Follow-Up: at Follow-Up Months 6, 12, 18, 24, 36
Percentage of Participants With CR With Incomplete Bone Marrow Recovery (CRi)
Participants with CRi were those who met all CR criteria (including BM examinations) but had persistent anemia, thrombocytopenia, or neutropenia apparently unrelated to chronic lymphocytic leukemia (CLL) but related to drug toxicity. CR: no ADPs and VSMs in PE; no general Sx; Lymph in peripheral blood \<4000/mm\^3; normalization of peripheral blood parameters: Neut \>1500/mm\^3, Plt \>100,000/mm\^3, Hb \>11 g/dL without transfusion; normocellular BM with \<30% Lymph; BM aspirate/biopsy with no evidence of infiltration of lymphoid nodules.
Time frame: Baseline up to progressive disease (PD) or death due to any cause, whichever occurred first (up to 92 months)
Percentage of Participants Who Died
Time frame: Baseline up to death due to any cause (up to 92 months)
Overall Survival (OS)
OS was defined as time from treatment start to death of the participant. For all other participants, the last follow-up available was taken as the last control. If the participant had not completed the study, the date of the last visit available was considered. OS was estimated using Kaplan-Meier (KM) methodology.
Time frame: Baseline up to death due to any cause (up to 92 months)
Percentage of Participants With PD or Death
PD was defined as new ADPs (1.5 centimeters \[cm\]), hepato-/splenomegaly (HSM), Richter syndrome (RS), or other infiltrated organs; greater than or equal to (\>/=) 50% increase in size of Baseline prior ADPs or HSM in participants with PR; Lymph increase \>/=50% in peripheral blood with B Lymph \>/=5000/mm\^3; cytopenia attributable to CLL. Progression of any cytopenia (not related to autoimmune cytopenia) reported as a 2-g/dL decrease in basal Hb, Hb \<10 g/dL, \>/=50% decrease in basal Plt count, or count \<100,000/mm\^3 at \>/=3 months post-treatment was defined as PD if BM biopsy confirmed infiltration of clonal CLL cells.
Time frame: Baseline up to PD or death due to any cause, whichever occurred first (up to 92 months)
Progression-Free Survival (PFS)
PFS was defined as time from start of study treatment to PD or death, whichever occurred first. For other participants, last follow-up available was taken as last control. If participant did not complete study, date of last visit available was considered. PFS was estimated using KM methodology. PD was defined as new ADPs (1.5 cm), HSM, RS, or other infiltrated organs; \>/=50% increase in size of Baseline prior ADPs or HSM in participants with PR; Lymph increase \>/=50% in peripheral blood with B Lymph \>/=5000/mm\^3; cytopenia attributable to CLL. Progression of any cytopenia (not related to autoimmune cytopenia) reported as a 2-g/dL decrease in basal Hb, Hb \<10 g/dL, \>/=50% decrease in basal Plt count, or count \<100,000/mm\^3 at \>/=3 months post-treatment was defined as PD if BM biopsy confirmed infiltration of clonal CLL cells.
Time frame: Baseline up to PD or death due to any cause, whichever occurred first (up to 92 months)
Treatment-Free Survival (TFS)
TFS was defined time from start of study treatment until participant received new chemotherapy/immunotherapy because of PD and to reduce the disease with palliative or curative intent. PD was defined as new ADPs (1.5 cm), HSM, RS, or other infiltrated organs; \>/=50% increase in size of Baseline prior ADPs or HSM in participants with PR; Lymph increase \>/=50% in peripheral blood with B Lymph \>/=5000/mm\^3; cytopenia attributable to CLL. Progression of any cytopenia (not related to autoimmune cytopenia) reported as a 2-g/dL decrease in basal Hb, Hb \<10 g/dL, \>/=50% decrease in basal Plt count, or count \<100,000/mm\^3 at \>/=3 months post-treatment was defined as PD if BM biopsy confirmed infiltration of clonal CLL cells.
Time frame: Baseline up to PD or death due to any cause, whichever occurred first (up to 92 months)
Duration of Response (DOR)
DOR: time from CR/PR to MRD/PD. PD: new ADP (1.5 cm), HSM, RS, other infiltrated organs or \>/=50% increase size in those with PR; blood Lymph increase \>/=50% with B Lymph \>/=5000/mm\^3; cytopenia due to CLL. Progression of (nonautoimmune) cytopenia: 2-g/dL decrease basal Hb, Hb \<10 g/dL, \>/=50% decrease basal Plt or \<100,000/mm\^3 at \>/=3 months post-treatment was PD if clonal CLL cell infiltration on BM biopsy. CR: no ADP/VSM in PE; no general Sx; blood Lymph \<4000/mm\^3; Neut \>1500/mm\^3; Plt \>100,000/mm\^3; Hb \>11 g/dL (no transfusion); normocellular BM with \<30% Lymph; BM aspirate/biopsy with no lymphoid nodule infiltration. PR: \>50% decrease blood Lymph; \>50% decrease in total sum up to 6 ADPs or baseline ADP of LD, no new/enlargement of prior ADP; \>50% decrease VSM; Neut \>1500/mm\^3 or \>50% increase; Plt \>100,000/mm\^3 or \>50% increase; Hb \>11.0 g/dL or \>50% increase (no transfusion). All CR criteria but persistent anemia or thrombocytopenia was PR. MRD: Lymph \>0.01% of blood/BM WBCs.
Time frame: From first CR or PR up to detectable MRD or disease occurrence/PD, whichever occurred first (up to 92 months)
Percentage of Participants With Cluster of Differentiation (CD) 38 Cells >/=30% in Peripheral Blood
Percentages of participants with CD38 expression by \>/=30% of CLL cells during the Induction Phase, Maintenance Phase, and Follow-Up were reported.
Time frame: Post-Induction Phase: at 6 months; during Maintenance Phase: at Cycles 9, 12, 15, 18 (cycle length = 2 months); during Follow-Up: at Follow-Up Months 6, 12, 18, 24, 30, 36
Percentage of Participants With Genetic Abnormalities
Percentages of participants with genetic abnormalities (deletion 6q, deletion 11q22-q23, deletion p53, trisomy 12, and deletion 13q14) in the course of the disease during the Induction Phase and Maintenance Phase were reported.
Time frame: Post-Induction Phase: at 6 months; during Maintenance Phase: at Cycles 9, 12, 15, 18 (cycle length = 2 months)
Percentage of Participants With Positive and Negative Zeta-Chain-Associated Protein Kinase 70 (ZAP-70) Expression
Percentages of participants with positive and negative ZAP-70 expression during the Induction Phase, Maintenance Phase, and Follow-Up were reported. Positive ZAP-70 was defined as ZAP-70 expression by \>/=20% of CLL cells. Negative ZAP-70 was defined as ZAP-70 expression by \<20% of CLL cells.
Time frame: Post-Induction Phase: at 6 months; during Maintenance Phase: at Cycles 9, 12, 15, 18 (cycle length = 2 months); during Follow-Up: at Follow-Up Months 6, 12, 18, 24, 30, 36
Percentage of Participants With Immunoglobulin Heavy Locus (IgH) Rearrangement
Percentages of participants with IgH rearrangement during the Induction Phase, Maintenance Phase, and Follow-Up were reported.
Time frame: Post-Induction Phase: at 6 months; during Maintenance Phase: at Cycles 9, 12, 15, 18 (cycle length = 2 months); during Follow-Up: at Follow-Up Months 6, 12, 18, 24, 30, 36
| Milestone | Rituximab + Fludarabine + Cyclophosphamide |
|---|---|
| Started | 86 |
| Safety population | 86 |
| Intent-to-treat (itt) population | 84 |
| Completed | 74 |
| Not completed | 12 |
| Withdrew: Physician decision | 3 |
| Withdrew: Unacceptable toxicity | 6 |
| Withdrew: Disease progression | 1 |
| Withdrew: Eligibility criteria violation | 2 |
| Milestone | Rituximab + Fludarabine + Cyclophosphamide |
|---|---|
| Started | 74 |
| Completed | 42 |
| Not completed | 32 |
| Withdrew: Unacceptable toxicity | 16 |
| Withdrew: Disease progression | 9 |
| Withdrew: Physician decision | 1 |
| Withdrew: Protocol violation | 1 |
| Withdrew: Withdrawal by subject | 3 |
| Withdrew: Death | 2 |
CR was defined as no adenopathies (ADPs) and visceromegalies (VSMs) in physical examination (PE); no general symptoms (Sx); lymphocytes (Lymph) in peripheral blood less than (\<) 4000 per cubic millimeter (mm\^3); normalization of peripheral blood parameters: neutrophils (Neut) greater than (\>) 1500/mm\^3, platelets (Plt) \>100,000/mm\^3, hemoglobin (Hb) \>11 grams per deciliter (g/dL) without transfusion; normocellular bone marrow (BM) with \<30% Lymph; BM aspirate/biopsy with no evidence of infiltration of lymphoid nodules.
| Percentage of Participants | Rituximab + Fludarabine + Cyclophosphamide |
|---|---|
| Percentage of Participants With CR Achieved After the Rituximab, Fludarabine, and Cyclophosphamide Regimen | 95.2 (88.25 to 98.69) |
CR was defined as no ADPs and VSMs in PE; no general Sx; Lymph in peripheral blood \<4000/mm\^3; normalization of peripheral blood parameters: Neut \>1500/mm\^3, Plt \>100,000/mm\^3, Hb \>11 g/dL without transfusion; normocellular BM with \<30% Lymph; BM aspirate/biopsy with no evidence of infiltration of lymphoid nodules. PR was defined as decrease \>50% in Lymph in peripheral blood; reduction in ADPs \>50% in total sum of up to 6 ADPs or in the baseline ADP of largest diameter (LD), no new ADP or enlargement of a prior ADP; \>50% decrease in VSM; Neut \>1500/mm\^3 or \>50% increase from Baseline; Plt \>100,000/mm\^3 or \>50% increase from Baseline; Hb \>11.0 g/dL or \>50% increase from Baseline value without transfusion. Participants who met all CR criteria but had persistent anemia or thrombocytopenia were considered as PR.
| Percentage of Participants | Rituximab + Fludarabine + Cyclophosphamide |
|---|---|
| Post-IP: CR | 75.0 |
| Post-IP: PR | 13.1 |
| MP (9 Cycles): CR | 89.4 |
| MP (9 Cycles): PR | 6.4 |
| MP (12 Cycles): CR | 87.9 |
| MP (12 Cycles): PR | 6.1 |
| MP (15 Cycles): CR | 90.9 |
| MP (15 Cycles): PR | 4.5 |
| MP (18 Cycles): CR | 88.1 |
| MP (18 Cycles): PR | 8.5 |
| 6 Months FU: CR | 83.3 |
| 6 Months FU: PR | 0.0 |
| 12 Months FU: CR | 94.4 |
| 12 Months FU: PR | 0.0 |
| 18 Months FU: CR | 100.0 |
| 18 Months FU: PR | 0.0 |
| 24 Months FU: CR | 93.1 |
| 24 Months FU: PR | 0.0 |
| 30 Months FU: CR | 100.0 |
| 30 Months FU: PR | 0.0 |
| 36 Months FU: CR | 100.0 |
| 36 Months FU: PR | 0.0 |
CR: no ADPs and VSMs in PE; no general Sx; Lymph in peripheral blood \<4000/mm\^3; normalization of peripheral blood parameters: Neut \>1500/mm\^3, Plt \>100,000/mm\^3, Hb \>11 g/dL without transfusion; normocellular BM with \<30% Lymph; BM aspirate/biopsy with no evidence of infiltration of lymphoid nodules. PR: decrease \>50% in Lymph in peripheral blood; reduction in ADPs \>50% in total sum of up to 6 ADPs or in the baseline ADP of largest diameter (LD), no new ADP or enlargement of a prior ADP; \>50% decrease in VSM; Neut \>1500/mm\^3 or \>50% increase from Baseline; Plt \>100,000/mm\^3 or \>50% increase from Baseline; Hb \>11.0 g/dL or \>50% increase from Baseline value without transfusion. Participants who met all CR criteria but had persistent anemia or thrombocytopenia were considered as PR. Negative MRD: Lymph \<0.01% of all white blood cells (WBCs) in blood or BM after two consecutive measurements. Analysis performed only in blood during the Maintenance Phase and Follow-Up.
| Percentage of Participants | Rituximab + Fludarabine + Cyclophosphamide |
|---|---|
| Post-IP: Blood MRD Negative | 100.0 |
| Post-IP: BM MRD Negative | 100.0 |
| MP (9 Cycles): Blood MRD Negative | 100.0 |
| MP (12 Cycles): Blood MRD Negative | 100.0 |
| MP (15 Cycles): Blood MRD Negative | 100.0 |
| MP (18 Cycles): Blood MRD Negative | 100.0 |
| 6 Months FU: Blood MRD Negative | 100.0 |
| 12 Months FU: Blood MRD Negative | 100.0 |
| 18 Months FU: Blood MRD Negative | 100.0 |
| 24 Months FU: Blood MRD Negative | 100.0 |
| 36 Months FU: Blood MRD Negative | 100.0 |
Participants with CRi were those who met all CR criteria (including BM examinations) but had persistent anemia, thrombocytopenia, or neutropenia apparently unrelated to chronic lymphocytic leukemia (CLL) but related to drug toxicity. CR: no ADPs and VSMs in PE; no general Sx; Lymph in peripheral blood \<4000/mm\^3; normalization of peripheral blood parameters: Neut \>1500/mm\^3, Plt \>100,000/mm\^3, Hb \>11 g/dL without transfusion; normocellular BM with \<30% Lymph; BM aspirate/biopsy with no evidence of infiltration of lymphoid nodules.
| Percentage of Participants | Rituximab + Fludarabine + Cyclophosphamide |
|---|---|
| Percentage of Participants With CR With Incomplete Bone Marrow Recovery (CRi) | 7.1 |
| Percentage of Participants | Rituximab + Fludarabine + Cyclophosphamide |
|---|---|
| Percentage of Participants Who Died | 23.2 (5.72 to NA) |
OS was defined as time from treatment start to death of the participant. For all other participants, the last follow-up available was taken as the last control. If the participant had not completed the study, the date of the last visit available was considered. OS was estimated using Kaplan-Meier (KM) methodology.
| Years | Rituximab + Fludarabine + Cyclophosphamide |
|---|---|
| Overall Survival (OS) | 7.51 (7.5 to NA) |
PD was defined as new ADPs (1.5 centimeters \[cm\]), hepato-/splenomegaly (HSM), Richter syndrome (RS), or other infiltrated organs; greater than or equal to (\>/=) 50% increase in size of Baseline prior ADPs or HSM in participants with PR; Lymph increase \>/=50% in peripheral blood with B Lymph \>/=5000/mm\^3; cytopenia attributable to CLL. Progression of any cytopenia (not related to autoimmune cytopenia) reported as a 2-g/dL decrease in basal Hb, Hb \<10 g/dL, \>/=50% decrease in basal Plt count, or count \<100,000/mm\^3 at \>/=3 months post-treatment was defined as PD if BM biopsy confirmed infiltration of clonal CLL cells.
| Percentage of Participants | Rituximab + Fludarabine + Cyclophosphamide |
|---|---|
| Percentage of Participants With PD or Death | 39.29 (5.72 to NA) |
PFS was defined as time from start of study treatment to PD or death, whichever occurred first. For other participants, last follow-up available was taken as last control. If participant did not complete study, date of last visit available was considered. PFS was estimated using KM methodology. PD was defined as new ADPs (1.5 cm), HSM, RS, or other infiltrated organs; \>/=50% increase in size of Baseline prior ADPs or HSM in participants with PR; Lymph increase \>/=50% in peripheral blood with B Lymph \>/=5000/mm\^3; cytopenia attributable to CLL. Progression of any cytopenia (not related to autoimmune cytopenia) reported as a 2-g/dL decrease in basal Hb, Hb \<10 g/dL, \>/=50% decrease in basal Plt count, or count \<100,000/mm\^3 at \>/=3 months post-treatment was defined as PD if BM biopsy confirmed infiltration of clonal CLL cells.
| Years | Rituximab + Fludarabine + Cyclophosphamide |
|---|---|
| Progression-Free Survival (PFS) | 6.96 (5.72 to NA) |
TFS was defined time from start of study treatment until participant received new chemotherapy/immunotherapy because of PD and to reduce the disease with palliative or curative intent. PD was defined as new ADPs (1.5 cm), HSM, RS, or other infiltrated organs; \>/=50% increase in size of Baseline prior ADPs or HSM in participants with PR; Lymph increase \>/=50% in peripheral blood with B Lymph \>/=5000/mm\^3; cytopenia attributable to CLL. Progression of any cytopenia (not related to autoimmune cytopenia) reported as a 2-g/dL decrease in basal Hb, Hb \<10 g/dL, \>/=50% decrease in basal Plt count, or count \<100,000/mm\^3 at \>/=3 months post-treatment was defined as PD if BM biopsy confirmed infiltration of clonal CLL cells.
| Years | Rituximab + Fludarabine + Cyclophosphamide |
|---|---|
| Treatment-Free Survival (TFS) | 4.13 (2.98 to 4.87) |
DOR: time from CR/PR to MRD/PD. PD: new ADP (1.5 cm), HSM, RS, other infiltrated organs or \>/=50% increase size in those with PR; blood Lymph increase \>/=50% with B Lymph \>/=5000/mm\^3; cytopenia due to CLL. Progression of (nonautoimmune) cytopenia: 2-g/dL decrease basal Hb, Hb \<10 g/dL, \>/=50% decrease basal Plt or \<100,000/mm\^3 at \>/=3 months post-treatment was PD if clonal CLL cell infiltration on BM biopsy. CR: no ADP/VSM in PE; no general Sx; blood Lymph \<4000/mm\^3; Neut \>1500/mm\^3; Plt \>100,000/mm\^3; Hb \>11 g/dL (no transfusion); normocellular BM with \<30% Lymph; BM aspirate/biopsy with no lymphoid nodule infiltration. PR: \>50% decrease blood Lymph; \>50% decrease in total sum up to 6 ADPs or baseline ADP of LD, no new/enlargement of prior ADP; \>50% decrease VSM; Neut \>1500/mm\^3 or \>50% increase; Plt \>100,000/mm\^3 or \>50% increase; Hb \>11.0 g/dL or \>50% increase (no transfusion). All CR criteria but persistent anemia or thrombocytopenia was PR. MRD: Lymph \>0.01% of blood/BM WBCs.
| Years | Rituximab + Fludarabine + Cyclophosphamide |
|---|---|
| Duration of Response (DOR) | NA (NA to NA) |
Percentages of participants with CD38 expression by \>/=30% of CLL cells during the Induction Phase, Maintenance Phase, and Follow-Up were reported.
| Percentage of Participants | Rituximab + Fludarabine + Cyclophosphamide |
|---|---|
| Post-IP | 47.6 |
| MP (9 Cycles) | 44.4 |
| MP (12 Cycles) | 45.5 |
| MP (15 Cycles) | 47.6 |
| MP (18 Cycles) | 47.4 |
| 6 Months FU | 66.7 |
| 12 Months FU | 45.7 |
| 18 Months FU | 100.0 |
| 24 Months FU | 41.4 |
| 30 Months FU | 50.0 |
| 36 Months FU | 35.5 |
Percentages of participants with genetic abnormalities (deletion 6q, deletion 11q22-q23, deletion p53, trisomy 12, and deletion 13q14) in the course of the disease during the Induction Phase and Maintenance Phase were reported.
| Percentage of Participants | Rituximab + Fludarabine + Cyclophosphamide |
|---|---|
| Post-IP: Deletion 6q | 3.6 |
| Post-IP: Deletion 11q22-q23 | 26.2 |
| Post-IP: Deletion p53 | 4.8 |
| Post-IP: Trisomy 12 | 15.5 |
| Post-IP: Deletion 13q14 | 50.0 |
| MP (9C): Deletion 6q | 4.3 |
| MP (9C): Deletion 11q22-q23 | 25.5 |
| MP (9C): Deletion p53 | 0.0 |
| MP (9C): Trisomy 12 | 17.0 |
| MP (9C): Deletion 13q14 | 55.3 |
| MP (12C): Deletion 6q | 3.0 |
| MP (12C): Deletion 11q22-q23 | 21.2 |
| MP (12C): Deletion p53 | 0.0 |
| MP (12C): Trisomy 12 (n= 33) | 21.2 |
| MP (12C): Deletion 13q14 | 51.5 |
| MP (15C): Deletion 6q | 4.5 |
| MP (15C): Deletion 11q22-q23 | 31.8 |
| MP (15C): Deletion p53 | 0.0 |
| MP (15C): Trisomy 12 | 18.2 |
| MP (15C): Deletion 13q14 | 59.1 |
| MP (18C): Deletion 6q | 3.4 |
| MP (18C): Deletion 11q22-q23 | 23.7 |
| MP (18C): Deletion p53 | 0.0 |
| MP (18C): Trisomy 12 | 18.6 |
| MP (18C): Deletion 13q14 | 49.2 |
Percentages of participants with positive and negative ZAP-70 expression during the Induction Phase, Maintenance Phase, and Follow-Up were reported. Positive ZAP-70 was defined as ZAP-70 expression by \>/=20% of CLL cells. Negative ZAP-70 was defined as ZAP-70 expression by \<20% of CLL cells.
| Percentage of Participants | Rituximab + Fludarabine + Cyclophosphamide |
|---|---|
| Post-IP: Positive | 57.3 |
| Post-IP: Negative | 42.7 |
| MP (9 Cycles): Positive | 57.5 |
| MP (9 Cycles): Negative | 42.5 |
| MP (12 Cycles): Positive | 62.1 |
| MP (12 Cycles): Negative | 37.9 |
| MP (15 Cycles): Positive | 57.1 |
| MP (15 Cycles): Negative | 42.9 |
| MP (18 Cycles): Positive | 54.9 |
| MP (18 Cycles): Negative | 45.1 |
| 6 Months FU: Positive | 63.6 |
| 6 Months FU: Negative | 36.4 |
| 12 Months FU: Positive | 60.0 |
| 12 Months FU: Negative | 40.0 |
| 18 Months FU: Positive | 100.0 |
| 18 Months FU: Negative | 0.0 |
| 24 Months FU: Positive | 59.3 |
| 24 Months FU: Negative | 40.7 |
| 30 Months FU: Positive | 100.0 |
| 30 Months FU: Negative | 0.0 |
| 36 Months FU: Positive | 57.1 |
| 36 Months FU: Negative | 42.9 |
Percentages of participants with IgH rearrangement during the Induction Phase, Maintenance Phase, and Follow-Up were reported.
| Percentage of Participants | Rituximab + Fludarabine + Cyclophosphamide |
|---|---|
| Post-IP | 36.2 |
| MP (9 Cycles) | 37.1 |
| MP (12 Cycles) | 20.0 |
| MP (15 Cycles) | 29.4 |
| MP (18 Cycles) | 33.3 |
| 6 Months FU | 100.0 |
| 12 Months FU | 37.9 |
| 18 Months FU | 50.0 |
| 24 Months FU | 33.3 |
| 30 Months FU | 0.0 |
| 36 Months FU | 45.8 |
Collected over Baseline through end of Follow-Up (up to 92 months). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Rituximab + Fludarabine + Cyclophosphamide | — | 35/86 (40.7%) | 82/86 (95.3%) |
| Event | Rituximab + Fludarabine + Cyclophosphamide |
|---|---|
| Febrile neutropeniaBlood and lymphatic system disorders | 8/86 |
| PneumoniaInfections and infestations | 7/86 |
| PyrexiaGeneral disorders | 6/86 |
| InfluenzaInfections and infestations | 2/86 |
| Respiratory tract infectionInfections and infestations | 2/86 |
| AnaemiaBlood and lymphatic system disorders | 1/86 |
| NeutropeniaBlood and lymphatic system disorders | 1/86 |
| Myocardial infarctionCardiac disorders | 1/86 |
| Crohn's diseaseGastrointestinal disorders | 1/86 |
| DiarrhoeaGastrointestinal disorders | 1/86 |
| Event | Rituximab + Fludarabine + Cyclophosphamide |
|---|---|
| NeutropeniaBlood and lymphatic system disorders | 52/86 |
| PyrexiaGeneral disorders | 31/86 |
| NasopharyngitisInfections and infestations | 27/86 |
| NauseaGastrointestinal disorders | 26/86 |
| LymphopeniaBlood and lymphatic system disorders | 24/86 |
| ThrombocytopeniaBlood and lymphatic system disorders | 18/86 |
| DiarrhoeaGastrointestinal disorders | 16/86 |
| LeukopeniaBlood and lymphatic system disorders | 15/86 |
| VomitingGastrointestinal disorders | 15/86 |
| AstheniaGeneral disorders | 14/86 |
Intent-to-Treat (ITT) Population included all participants who received at least one dose of study drug and met inclusion/exclusion criteria.
| Age, Continuous(Years) | Rituximab + Fludarabine + Cyclophosphamide |
|---|---|
| Mean | 57.92 ± 7.87 |
| Sex: Female, Male(Participants) | Rituximab + Fludarabine + Cyclophosphamide |
|---|---|
| Female | 27 |
| Male | 57 |
Ran from Nov 2007 to primary completion in May 2016, 101 months.
Results were first posted in Jan 2019, 2 years 7 months after primary completion.
Of 41 industry-sponsored phase 2 interventional studies under Leukemia, Lymphocytic, Chronic, B-Cell, half reached primary completion within 55 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 87. This study's 101 months is above that.
Counting every sponsor, half of 249 studies reached it within 73 months; a quarter within 41 and three quarters within 114.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Cyclophosphamide · Fludarabine · Rituximab
Leukemia, Lymphocytic, Chronic, B-Cell →